🇺🇸 FDA

Intelligence · Clinical Pipeline

Oncology · Phase II

Oncology programs at Phase II — ClinicalTrials.gov pipeline intelligence.

Programs
2,640

Quick answer

Oncology Phase II programs: NovaPharmaNews indexes 2,640 matching clinical development programs from ClinicalTrials.gov with sponsor, modality, and NCT cross-links.

Top sponsors

Page 40 of 55

  1. Phase I/II First-In-Human open-label trial to assess safety and efficacy of STX-241 in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) resistant to EGFR tyrosine kinase inhibitors (TKIs)

    Pierre Fabre Medicament

    locally advanced or metastatic non-small cell lung cancer (NSCLC) resistant to EGFR tyrosine kinase inhibitors (TKIs)

    phase 2 other active

    1 trial

  2. Piqray 50 mg and 200 mg film-coated tablets

    Wuhan Createrna Science and Technology Co., Ltd

    metasatic breast cancer, hormon positive, her 2 negative

    phase 2 small molecule active

    1 trial

  3. Pirarubicin

    The First People's Hospital of Lianyungang

    Upper Tract Urothelial Carcinoma

    phase 2 small molecule active

    1 trial

  4. Placebo

    Cardiff Oncology

    Metastatic Breast Cancer

    phase 2 small molecule terminated

    1 trial

  5. Placebo

    Hospital Authority, Hong Kong

    STOMACH NEOPLASM

    phase 2 small molecule active

    1 trial

  6. Placebo

    NovaBridge Biosciences

    Breast Cancer

    phase 2 small molecule terminated

    1 trial

  7. Placebo for ponsegromab (PF-06946860) solution for injection, Ponsegromab (PF-06946860)

    Pfizer Australia Pty Ltd

    Cancer cachexia

    phase 2 small molecule active

    1 trial

  8. Placebo to V940, KEYTRUDA 25 mg/mL concentrate for solution for infusion, mRNA-4157

    Merck Sharp and Dohme

    Melanoma

    phase 2 small molecule active

    1 trial

  9. Pluvicto 1 000 MBq/mL solution for injection/infusion

    Ningbo Cancer Hospital

    Clear Cell Renal Cell Carcinoma (ccRCC)

    phase 2 small molecule active

    1 trial

  10. Pluvicto 1 000 MBq/mL solution for injection/infusion, Locametz 25 micrograms kit for radiopharmaceutical preparation

    Novartis Pharmaceuticals

    Progressive PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC) with moderate and severe renal impairment and with normal renal function.

    phase 2 small molecule active

    1 trial

  11. Polivy 30 mg powder for concentrate for solution for infusion., Epcoritamab (GEN3013), Truxima 100 mg concentrate for solution for infusion, IMBRUVICA 140 mg hard capsules, Golcadomide, Revlimid 10 mg hard capsules, IMBRUVICA 140 mg hard capsules, PIRTOBRUTINIB, Cyclophosphamide Injection 500 mg., Venetoclax, Venetoclax, Epcoritamab (GEN3013), Revlimid 25 mg hard capsules, Venetoclax, Decortin® H 20 mg Tabletten, Truxima 500 mg concentrate for solution for infusion, Decortin® H 5 mg Tabletten, Adriblastin®

    AbbVie Deutschland GmbH & Co. KG

    B-cell Non-Hodgkin's lymphoma, diffuse large B-cell lymphoma

    phase 2 small molecule active

    1 trial

  12. Polivy 30 mg powder for concentrate for solution for infusion., Mosunetuzumab, Mosunetuzumab, RoActemra 20 mg/mL concentrate for solution for infusion, Mosunetuzumab, Mosunetuzumab, Polivy 140 mg powder for concentrate for solution for infusion., Mosunetuzumab, Mosunetuzumab

    Hoffmann-La Roche

    Diffuse Large B-Cell Lymphoma (DLBCL)

    phase 2 small molecule active

    1 trial

  13. Ponatinib

    Cardiff Oncology

    Acute Lymphoblastic Leukemia, Adult

    phase 2 small molecule active

    1 trial

  14. Ponatinib

    Takeda

    Chronic Myeloid Leukemia

    phase 2 small molecule completed

    1 trial

  15. Ponatinib

    Takeda

    Myeloid Leukemia, Chronic, Chronic Phase

    phase 2 small molecule completed

    1 trial

  16. Ponatinib

    Takeda

    Pediatric Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ALL)

    phase 2 small molecule terminated

    1 trial

  17. Posaconazol STADA 100 mg magensaftresistente Tabletten, S65487 Solution for infusion 100 mg, Vidaza 25 mg/ml powder for suspension for injection

    The George Institute

    Acute Myeloid Leukemia (AML)

    phase 2 small molecule active

    1 trial

  18. Postoperative adjuvant lenvatinib

    The First People's Hospital of Lianyungang

    Hepatocellular Carcinoma (HCC)

    phase 2 small molecule active

    1 trial

  19. Powder for concentrate for solution for infusion, Venclyxto 50 mg film-coated tablets, Zyloric 300 mg Tablets, Venclyxto 10 mg film-coated tablets, Venclyxto 50 mg film-coated tablets, Venclyxto 50 mg film-coated tablets, Fasturtec 1.5 mg/ml powder and solvent for concentrate for solution for infusion., Venclyxto 10 mg film-coated tablets, Venclyxto 10 mg film-coated tablets, Venclyxto 100 mg film-coated tablets, Venclyxto 50 mg film-coated tablets, Venclyxto 10 mg film-coated tablets, Zyloric 100 mg Tablet

    The George Institute

    "Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)/AML, or Chronic Myelomonocytic Leukemia (CMML)"

    phase 2 small molecule active

    1 trial

  20. Pre-operative chemotherapy

    Nanjing Zenshine Pharmaceuticals

    Gastric Cancers

    phase 2 small molecule active

    1 trial

  21. Pre-operative chemotherapy

    The First People's Hospital of Lianyungang

    Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  22. Pred Forte 10 mg/ml colirio en suspensión, Pred Forte 1% w/v, Eye Drops Suspension, Brimonidine Tartrate 0.2% w/v Eye Drops., Alphagan 2 mg/ml colirio en solución, IMGN151

    AbbVie Deutschland GmbH & Co. KG

    Recurrent endometrial cancer, recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer (EOC), recurrent cervical cancer

    phase 2 small molecule active

    1 trial

  23. ProSpare

    United Therapeutics Europe Ltd

    Cancer

    phase 2 other active

    1 trial

  24. Probiotics Compound (Biolosion)

    Sun Yat-sen University

    Advanced Urothelial Carcinoma

    phase 2 small molecule active

    1 trial

  25. Programmed Cell Death Protein 1 Inhibitor

    Chinese University of Hong Kong

    Locally Advanced Esophageal Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  26. Proleukin 18 x 106 UI Polvere per soluzione iniettabile o per infusione, DC-VACCINE_IRSTIRCCS

    Istituto Gentili S.r.l.

    neuroendocrine tumors, soft tissue sarcoma

    phase 2 small molecule active

    1 trial

  27. Prostate alone IMRT

    United Therapeutics Europe Ltd

    Prostate Cancer

    phase 2 other active

    1 trial

  28. Pucotenlimab

    Sun Yat-sen University

    Colorectal Cancer (CRC)

    phase 2 small molecule active

    1 trial

  29. Pucotenlimab

    Zhejiang Provincial People's Hospital

    Pancreatic Cancer

    phase 2 mab active

    1 trial

  30. Pulmonary Rehabilitation (PR)

    United Therapeutics Europe Ltd

    Non-small Cell Lung Cancer Stage III

    phase 2 other active

    1 trial

  31. Puregon 300 IU/0.36 mL solution for injection, Cetrotide 0.25 mg powder and solvent for solution for injection, NOLVADEX 10 mg, comprimé pelliculé, Ovitrelle 250 micrograms solution for injection in pre-filled pen

    CERO THERAPEUTICS HOLDINGS, INC.

    Breast cancer

    phase 2 small molecule active

    1 trial

  32. Pyrotinib

    The First People's Hospital of Lianyungang

    Breast Cancer

    phase 2 small molecule active

    1 trial

  33. Pyrotinib, trastuzumab, paclitaxel-albumin

    The First People's Hospital of Lianyungang

    Breast Cancer

    phase 2 small molecule active

    1 trial

  34. QINLOCK 50 mg tablets

    Lacuna Pharma Pty Ltd

    Advanced gastrointestinal stromal tumor (GIST)

    phase 2 small molecule active

    1 trial

  35. QL1706

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Platinum-resistant Recurrent Ovarian Cancer

    phase 2 small molecule active

    1 trial

  36. QL1706

    The First People's Hospital of Lianyungang

    Local Advanced Esophageal Cancer

    phase 2 small molecule active

    1 trial

  37. QL1706 (Iparomlimab/Tuvonralimab)

    The First People's Hospital of Lianyungang

    Gastric Cancer Stage III

    phase 2 small molecule active

    1 trial

  38. QL1706 (bispecific antibody targeting PD-1 and CLTA-4)

    The First People's Hospital of Lianyungang

    Esophageal Squamous Cell Carcinoma (ESCC)

    phase 2 small molecule active

    1 trial

  39. Quemliclustat

    Arcus Biosciences

    Oligometastatic Prostate Cancer

    phase 2 small molecule active

    1 trial

  40. Quizartinib

    Daiichi Sankyo

    Acute Myeloid Leukemia

    phase 2 small molecule active

    1 trial

  41. RC48-ADC

    Chinese University of Hong Kong

    Muscle Invasive Bladder Carcinoma

    phase 2 small molecule active

    1 trial

  42. RD14-01

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Solid Tumor

    phase 2 mab active

    1 trial

  43. REGN10597

    Regeneron UK Limited

    Melanoma

    phase 2 small molecule active

    1 trial

  44. REGN15505

    Regeneron UK Limited

    Metastatic Castration-Resistant Prostate Cancer (mCRPC)

    phase 2 small molecule active

    1 trial

  45. REGN2810

    Regeneron UK Limited

    Prostate Cancer Metastatic

    phase 2 small molecule active

    1 trial

  46. REGN4336

    Regeneron UK Limited

    Metastatic Castration-resistant Prostate Cancer

    phase 2 small molecule active

    1 trial

  47. REGN5093

    Lacuna Pharma Pty Ltd

    MET-altered non-small cell lung cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  48. REGN5668

    Regeneron UK Limited

    Ovarian Cancer

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many oncology Phase II programs exist?

2,640 programs match both the therapeutic area and stage filters in our published index.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.